Search Results - "Blommestein, Hedwig M."

Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma by van Beurden-Tan, Chrissy H Y, Franken, Margreet G, Blommestein, Hedwig M, Uyl-de Groot, Carin A, Sonneveld, Pieter

“…Purpose Since 2000, many new treatment options have become available for relapsed and/or refractory multiple myeloma (R/R MM) after a long period in which…”
Get full text

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis by Blommestein, Hedwig M, van Beurden-Tan, Chrissy H Y, Franken, Margreet G, Uyl-de Groot, Carin A, Sonneveld, Pieter, Zweegman, Sonja

“…Decision making for patients with multiple myeloma (MM) not transplant eligible (NTE) is complicated by a lack of head-to-head comparisons of standards of…”
Get full text

Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion by Mihajlović, Jovan, PhD, Bax, Pieter, PharmD, van Breugel, Erwin, PharmD, Blommestein, Hedwig M., PhD, Hoogendoorn, Mels, PhD, Hospes, Wobbe, PharmD, Postma, Maarten J., PhD

“…Abstract Purpose The goal of this study is to identify and compare all direct costs of intravenous and subcutaneous rituximab given to patients with diffuse…”
Get full text

Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences by de Groot, Saskia, MSc, van der Linden, Naomi, PhD, Franken, Margreet G., PhD, Blommestein, Hedwig M., MSc, Leeneman, Brenda, MSc, van Rooijen, Ellen, MD, (Koos) van der Hoeven, J.J.M., MD, PhD, Wouters, Michel W., MD, PhD, Westgeest, Hans M., MD, Uyl-de Groot, Carin A., PhD

“…Abstract Objectives The aim of this article was to provide practical guidance in setting up patient registries to facilitate real-world data collection for…”
Get full text

Cost-effectiveness: maximizing impact by meticulous data by Blommestein, Hedwig M., Zweegman, Sonja

Get full text

Policymaker, Please Consider Your Needs Carefully: Does Outcomes Research in Relapsed or Refractory Multiple Myeloma Reduce Policymaker Uncertainty Regarding Value for Money of Bortezomib? by Franken, Margreet G., MSc, Gaultney, Jennifer G., MPH, MSc, Blommestein, Hedwig M., MSc, Huijgens, Peter C., PhD, MD, Sonneveld, Pieter, PhD, MD, Redekop, William K., PhD, Uyl-de Groot, Carin A., PhD

“…Abstract Introduction Dutch policy regulations require outcomes research for the assessment of appropriate drug use and cost-effectiveness after 4 years of…”
Get full text

Changes in survival in de novo metastatic cancer in an era of new medicines by Luyendijk, Marianne, Visser, Otto, Blommestein, Hedwig M, de Hingh, Ignace H J T, Hoebers, Frank J P, Jager, Agnes, Sonke, Gabe S, de Vries, Elisabeth G E, Uyl-de Groot, Carin A, Siesling, Sabine

“…Abstract Background Over the past decades, the therapeutic landscape has markedly changed for patients with metastatic solid cancer, yet few studies have…”
Get full text

Changes in income and employment after diagnosis among patients with multiple myeloma in The Netherlands by Bennink, Christine, Brink, Mirian, Duijts, Saskia F.A., Scheurer, Hans, Sonneveld, Pieter, Blommestein, Hedwig M.

“…Due to new treatment options, survival rates in multiple myeloma (MM) are improving. Consequently, maintaining work and income is becoming more important for…”
Get full text

Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands by Chen, Yi Hsuan, Blommestein, Hedwig M, Klazenga, Reinder, Uyl-de Groot, Carin, van Vulpen, Marco

“…Proton therapy (PT) has characteristics that enable the sparing of healthy, non-cancerous tissue surrounding the radiotherapy target volume better from…”
Get full text

Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer by Luyendijk, Marianne, Jager, Agnes, Buijs, Sanne M., Siesling, Sabine, Groot, Carin A. Uyl-de, Blommestein, Hedwig M.

“…Background Gene expression profiling tests can predict the risk of disease recurrence and select patients who are expected to benefit from therapy, while…”
Get full text

Health‐related quality of life in patients with steroid‐refractory acute graft‐versus‐host disease by Leeneman, Brenda, Blommestein, Hedwig M., Dongen‐Leunis, Annemieke, Algeri, Mattia, Fibbe, Willem E., Oosten, Liesbeth, Uyl‐de Groot, Carin A., Thielen, Frederick W.

“…Background Evidence regarding health‐related quality of life (HRQoL) in patients with steroid‐refractory acute graft‐versus‐host disease (SR‐aGvHD) is lacking…”
Get full text

A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry by Blommestein, Hedwig M., Franken, Margreet G., Uyl-de Groot, Carin A.

“…Decision makers increasingly request evidence on the real-world cost effectiveness of a new treatment. There is, however, a lack of practical guidance on how…”
Get full text

Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review by Luyendijk, Marianne, Vernooij, Robin W.M., Blommestein, Hedwig M., Siesling, Sabine, Uyl-de Groot, Carin A.

“…Large secondary databases, such as those containing insurance claims data, are increasingly being used to compare the effects and costs of treatments in…”
Get full text

A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma by Seefat, Maarten R., Cucchi, David G. J., Dirven, Stijn, Groen, Kaz, Zweegman, Sonja, Blommestein, Hedwig M.

“…Background: Novel therapies for multiple myeloma (MM) promise to improve outcomes but are also associated with substantial increasing costs. Evidence regarding…”
Get full text

A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands by Issa, Djamila E., Dinmohamed, Avinash G., Wondergem, Marielle J., Blommestein, Hedwig M., Huijgens, Peter C., Lugtenburg, Pieternella J., Visser, Otto, Zweegman, Sonja, Chamuleau, Martine E. D.

“…Randomized controlled trials have studied different dose-intensity and dose-interval regimens of R-CHOP for patients with diffuse large B-cell lymphoma…”
Get full text

Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma by Leeneman, Brenda, Franken, Margreet G., Coupé, Veerle M.H., Hendriks, Mathijs P., Kruit, Wim, Plaisier, Peter W., van Ruth, Serge, Verstijnen, José A.M.C., Wouters, Michel W.J.M., Blommestein, Hedwig M., Uyl – de Groot, Carin A.

“…To investigate stage-specific survival from diagnosis, stage-specific disease recurrence, and post-recurrence survival in patients diagnosed with localized and…”
Get full text

Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review by Chen, Yi Hsuan, Molenaar, Dominique, Uyl-de Groot, Carin A, van Vulpen, Marco, Blommestein, Hedwig M

“…Despite the need for a proper economic evaluation of new radiotherapies, the economic burden of radiotherapy-induced adverse effects remains unclear. A…”
Get full text

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal by Büyükkaramikli, Nasuh C., Blommestein, Hedwig M., Riemsma, Rob, Armstrong, Nigel, Clay, Fiona. J., Ross, Janine, Worthy, Gill, Severens, Johan, Kleijnen, Jos, Al, Maiwenn J.

“…The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ramucirumab (Cyramza ® , Eli Lilly and Company) to submit…”
Get full text

Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view by Thielen, Frederick W, Kersten, Marie-José, Kuizenga, Pim, Hoogendoorn, Mels, Posthuma, Eduardus FM, Stevens, Wendy BC, A Uyl-de Groot, Carin, Blommestein, Hedwig M

“…Efficacy of lenalidomide plus rituximab (R-LEN) compared to rituximab monotherapy (R-mono) for patients with previously treated follicular lymphoma (FL) was…”
Get full text

Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country by Thielen, Frederick W., Houwing, Maite E., Cnossen, Marjon H., al Hadithy‐Irgiztseva, Ilona A., Hazelzet, Jan A., Groot, Carin A. Uyl‐de, Pagter, Anne P.J., Blommestein, Hedwig M.

“…Background While multiple studies have examined the cost of health care for one aspect of sickle cell disease care, few have focussed on the overall cost of…”
Get full text